
    
      A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Efficacy Trial of a Single Dose of
      Live Oral Cholera Vaccine Candidate, PXVX0200 CVD 103-HgR Strain, in Preventing Cholera
      following Challenge with Vibrio cholerae O1 El Tor Inaba 10 Days or 3 Months after
      Vaccination in volunteers aged 18-45 years
    
  